[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

“We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS.”

http://www.ncbi.nlm.nih.gov/pubmed/26535431

http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/

Leave a Reply

Your email address will not be published. Required fields are marked *